Phenobarbital NDC 70752-164

NDC codes

FDA NDC Directory

Product NDC (as listed)70752-164Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70752-0164Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
70752-164-10	70752016410	100 TABLET in 1 BOTTLE (70752-164-10)Marketed from Sep 15, 2020
70752-164-11	70752016411	1000 TABLET in 1 BOTTLE (70752-164-11)Marketed from Sep 15, 2020
70752-164-14	70752016414	500 TABLET in 1 BOTTLE (70752-164-14)Marketed from Sep 15, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Phenobarbital
Generic name (nonproprietary): phenobarbital
Active ingredients: Phenobarbital — 97.2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: QUAGEN PHARMACEUTICALS LLC
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Sep 15, 2020
Listing expires: Dec 31, 2026
DEA schedule: CIV
Identifiers: Product ID 70752-164_234e0cf8-e1c9-47a2-8fa3-8a4db929c866SPL ID 234e0cf8-e1c9-47a2-8fa3-8a4db929c866SPL set ID 7e6853a4-478d-40e3-b041-4cff02a74c8cRxCUI 198086, 199164, 199167, 199168UNII YQE403BP4D

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470752016410 followed by a unit qualifier and the quantity

Package 70752-0164-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 16, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sedative Anticonvulsant – For the treatment of generalized and partial seizures.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)